Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
July 02, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
May 29, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Rainin Foundation Seeks Novel, Collaborative Research Into Inflammatory Bowel Disease
May 28, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation invites proposals for its Synergy Awards program from June 3 through September 16, 2019. This funding opportunity...
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
May 21, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
May 13, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
April 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Retains Renmark Financial Communications
March 12, 2019 23:46 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 12, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Kenneth Rainin Foundation Awards Over $2 Million For Collaborative IBD Research Projects
February 04, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation announced that it has awarded over $2 million in grants through its Synergy Awards program. This program encourages...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
November 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.; Nash Pharmaceuticals Inc.
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)...